Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

“…In the one-sided test, 75 patients per arm (assumder carcinoma who were ineligible for cisplatin-based ing that 10% of patients were not evaluable) were rechemotherapy; our results showed that this is an active quired to detect a 25% difference in response rates regimen in such a setting, with a favorable toxicity between the two arms, with an a error of 0.05 and a profile. 17 b error of 0.2. An expected overall response rate for Various randomized studies comparing cisplatinthe M-VAC arm of 70% was assumed based on prior based chemotherapy with carboplatin-containing regdata.…”

“…Hematologic toxicity associated future design of carboplatin-based regimens if higher with carboplatin can be better controlled when the response rates are to be obtained. 17,30,32 The more fadose is calculated individually for each patient based vorable toxicity profile of carboplatin could allow for on a projected AUC and according to the glomerular a significant increase in dose intensity and also allow filtration rate. 27,29 The minimal myelosuppression obfor testing of the hypothesis that with higher dose inserved in this study in the carboplatin arm could be tensities, increased response and results similar to explained not only by the use of Calvert's formula but those for cisplatin could be achieved.…”

Novel strategies for treating relapsed/refractory urothelial carcinoma

“…A Phase I/II study evaluated the combination of paclitaxel, cisplatin and gemcitabine (PCG) in 61 patients; the ORR was 78% with Phase I and II median survivals of 24 and 16 months, respectively [18]. A multicenter Phase III study coordinated by the European Organisation for Research and Treatment of Cancer randomized 627 patients with metastatic bladder cancer to receive GC or PCG [19–24]. While the PCG arm demonstrated a superior ORR (57% with PCG vs 46% with GC; p = 0.02), no significant difference was noted in either PFS or OS, although an unplanned subgroup analysis revealed that patients with a bladder primary tumor had an improvement in OS (p = 0.03) [24].…”

Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting

“…22 Trials of carboplatin-based regimens in patients with normal renal function have demonstrated encouraging ORRs in the range of 30% to 40%, but the CR rates are lower and they are paralleled by shorter median survivals of 8 months to 10 months. 23,24 These results appear inferior to those noted with M-VAC or GC, and therefore carboplatin should not be routinely substituted for cisplatin in patients who can receive cisplatin-based chemotherapy.…”